NRH, a potent NAD+ booster, improves glucose homeostasis and lipid metabolism in diet-induced obese mice though an active adenosine kinase pathway.

A preprint abstract from biorxiv.org discusses the potential benefits of a new NAD+ enhancer called dihydronicotinamide riboside (NRH) in treating obesity-induced metabolic syndrome. The study conducted on diet-induced obese mice found that administering NRH for 7 weeks improved glucose homeostasis, increased muscle insulin sensitivity, reduced hepatic gluconeogenesis, mobilized fat deposition, reduced circulating lipid, and improved white adipose function. These improvements were mediated by elevated NAD+ levels and sirtuin (SIRT) activities, particularly SIRT3. The study also found that inhibiting adenosine kinase (ADK), an enzyme in the NRH-induced NAD+ synthesis pathway, blocked the metabolic benefits of NRH. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]